Press release
Diabetic Macular Edema Market Massive Growth opportunity Ahead
Diabetic Macular Edema Market
Diabetic macular edema (DME) is one of the leading causes of vision impairment among people with diabetes, characterized by fluid leakage into the macula, the part of the retina responsible for sharp central vision. Left untreated, DME can cause progressive vision loss and blindness, severely impacting quality of life and productivity.
With over 530 million adults living with diabetes globally in 2024, the risk pool for DME continues to expand. The disease burden is particularly acute in developing nations, where diabetes incidence is accelerating, yet access to advanced ophthalmic care is limited. The evolution of treatments from laser photocoagulation to anti-VEGF therapies, corticosteroid implants, and emerging gene therapies has significantly improved outcomes. Between 2024 and 2034, the DME market is set for strong expansion, driven by therapeutic innovations, growing awareness, and broader access to ophthalmology services.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72052
Market Overview
• Market Size 2024: USD 4.9 billion (estimated)
• Forecasted Market Size 2034: USD 9.1 billion
• CAGR (2024-2034): 6.5%
Key Highlights
• Rising prevalence of diabetes and obesity fueling DME incidence.
• Strong adoption of anti-VEGF injections such as aflibercept, ranibizumab, and bevacizumab.
• Growth of sustained-release corticosteroid implants (Ozurdex, Iluvien) for refractory cases.
• Expanding pipeline of biosimilars and gene therapies aiming to improve affordability and long-term outcomes.
Segmentation Analysis
By Product
• Anti-VEGF agents (aflibercept, ranibizumab, bevacizumab, brolucizumab)
• Corticosteroid implants (dexamethasone implant, fluocinolone acetonide implant)
• Laser photocoagulation therapy
• Combination therapies (anti-VEGF + corticosteroids, anti-VEGF + laser)
• Gene therapies and pipeline biologics
By Platform
• Hospital pharmacies
• Retail pharmacies
• Specialty/ophthalmology clinics
• Online pharmacies
By Technology
• Intravitreal injections (anti-VEGF, corticosteroids)
• Sustained-release implants and drug delivery systems
• Laser-based therapies
• Gene therapy and regenerative medicine (pipeline)
By End Use
• Hospitals and ophthalmology centers
• Specialty eye clinics
• Homecare/tele-ophthalmology (screening and follow-up)
By Application
• Type 1 diabetes-related DME
• Type 2 diabetes-related DME
• Refractory/advanced DME
Summary:
Anti-VEGF therapy dominates the market today, but corticosteroid implants and gene therapies are expected to witness the fastest growth. Combination treatments are gaining traction as physicians aim to reduce injection frequency and enhance outcomes.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72052/diabetic-macular-edema-dme-market
Regional Analysis
North America
• Largest market share in 2024, driven by widespread access to advanced biologics and well-established diabetes screening programs.
• U.S. leads with high adoption of Eylea (aflibercept) and Lucentis (ranibizumab), alongside emerging biosimilars.
Europe
• Germany, France, and the UK represent key markets with robust reimbursement systems.
• Increasing use of sustained-release implants for patients with poor adherence.
Asia-Pacific
• Fastest-growing region (CAGR ~7.8%), owing to a rapidly rising diabetic population in India, China, and Southeast Asia.
• Expanding healthcare infrastructure and medical tourism driving adoption of advanced therapies.
Middle East & Africa
• Rising diabetes burden contributing to higher DME prevalence.
• Limited access to biologics, but government and NGO initiatives are improving availability.
Latin America
• Brazil and Mexico are regional leaders, with growing demand for anti-VEGF agents.
• Medical tourism and improved ophthalmology services fueling growth.
Summary:
While North America currently dominates revenues, Asia-Pacific will deliver the strongest incremental growth, supported by large patient populations and expanding healthcare access.
Market Dynamics
Key Growth Drivers
• Rising diabetes prevalence worldwide.
• Increased adoption of anti-VEGF therapies as first-line treatment.
• Technological innovation in long-acting implants and gene therapy.
• Expanding global ophthalmology infrastructure.
Key Challenges
• High cost of biologics limiting access in low- and middle-income countries.
• Frequent injection regimens impacting patient adherence.
• Unequal availability of trained ophthalmologists in emerging regions.
• Pricing pressure from biosimilars affecting branded drug revenues.
Latest Trends
• Development of longer-acting anti-VEGF formulations (e.g., aflibercept high-dose).
• Growing use of biosimilars to expand access and affordability.
• Adoption of AI-driven retinal screening tools and tele-ophthalmology.
• Expanding research into gene therapies offering potential long-term control.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72052
Competitor Analysis
Major Players
• Regeneron Pharmaceuticals, Inc. (Eylea - aflibercept)
• Genentech/Roche (Lucentis - ranibizumab; Susvimo - sustained-release implant)
• Novartis AG (Beovu - brolucizumab)
• Allergan/AbbVie Inc. (Ozurdex - dexamethasone implant)
• Alimera Sciences, Inc. (Iluvien - fluocinolone acetonide implant)
• Bayer AG (co-commercialization of aflibercept with Regeneron)
• Samsung Bioepis & Biogen (anti-VEGF biosimilars)
• Kodiak Sciences Inc. (long-acting biologics pipeline)
• Adverum Biotechnologies, Inc. (gene therapy research)
• Oxurion NV (retinal disease biologics pipeline)
Summary:
The DME market is dominated by anti-VEGF innovators like Regeneron, Roche, and Novartis, but new players are entering through biosimilars and gene therapies. The competitive focus is on extending treatment durability and reducing costs.
Conclusion
The diabetic macular edema (DME) market is projected to nearly double, reaching USD 9.1 billion by 2034, at a CAGR of 6.5%. The market is driven by diabetes prevalence, adoption of anti-VEGF agents, and innovation in sustained-release and gene-based therapies.
Key Takeaways:
• North America leads today, while Asia-Pacific grows fastest due to its large diabetic population.
• Anti-VEGF injections remain standard, but implants and gene therapies are reshaping the future.
• Biosimilars and AI-driven diagnostics will expand affordability and accessibility.
• Competitive strategies are focused on durability, affordability, and global access.
This report is also available in the following languages : Japanese (糖尿病黄斑浮腫(DME)市場), Korean (당뇨병성 황반부종(DME) 시장), Chinese (糖尿病黄斑水肿(DME)市场), French (Marché de l'œdème maculaire diabétique (OMD)), German (Markt für diabetisches Makulaödem (DME)), and Italian (Mercato dell'edema maculare diabetico (DME)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72052
Our More Reports:
Treatment-Resistant Depression (TRD) Market
https://exactitudeconsultancy.com/reports/72096/treatment-resistant-depression-trd-market
Developmental and Epileptic Encephalopathies DEE Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72100/developmental-and-epileptic-encephalopathies-dee-patient-pool-analysis-market
Parkinson's disease Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72102/parkinson-s-disease-patient-pool-analysis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Macular Edema Market Massive Growth opportunity Ahead here
News-ID: 4188351 • Views: …
More Releases from Exactitude Consultancy
Cystinosis Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Cystinosis is a rare, inherited lysosomal storage disorder caused by the accumulation of cystine within cells, leading to progressive damage to multiple organs, including the kidneys, eyes, muscles, pancreas, and thyroid. If left untreated, it results in renal Fanconi syndrome, growth retardation, photophobia, and eventually kidney failure. The disease is typically diagnosed in infancy or early childhood, and without intervention, life expectancy is severely reduced.
Over the past two decades, cysteamine-based…
Somatotropin Deficiency Market Growth, Applications, Innovations and Business Ou …
Introduction
Somatotropin deficiency, commonly referred to as growth hormone deficiency (GHD), is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the pituitary gland. It manifests in children as stunted growth and delayed development, and in adults as metabolic issues, decreased bone density, and reduced quality of life. While congenital cases are often diagnosed in childhood, acquired forms may arise later in life due to trauma, tumors,…
Endogenous Cushing's Syndrome Market to Reach USD 1.9 Billion by 2034
Endogenous Cushing's Syndrome (CS) is a rare but serious endocrine disorder caused by chronic exposure to elevated cortisol levels due to the body's own overproduction. Unlike exogenous cases induced by prolonged corticosteroid therapy, endogenous Cushing's syndrome arises from pituitary adenomas (Cushing's disease), adrenal tumors, or ectopic ACTH secretion. The condition is associated with significant morbidity-ranging from diabetes and hypertension to osteoporosis and cardiovascular complications-making early diagnosis and effective treatment critical.
Download…
Secondary Hyperparathyroidism Market Growth, Trends, Consumer Demand and Key Opp …
Introduction
Secondary hyperparathyroidism (SHPT) is a frequent and serious complication of chronic kidney disease (CKD), characterized by excessive secretion of parathyroid hormone (PTH) due to impaired calcium, phosphorus, and vitamin D metabolism. Left untreated, SHPT leads to mineral and bone disorders, cardiovascular complications, and poor quality of life for patients.
With the global CKD population rising sharply, particularly among patients on dialysis, the SHPT market has gained significant importance. Treatment approaches have…
More Releases for DME
Dimethyl Ether (DME) & R-DME Market Expansion and Future Trends | 2025 To 2034 O …
The Global Dimethyl Ether (DME) & R-DME Market Size, Scope, and Forecast 2025-2034 report is now part of Exactitude Consultancy's Market Research collection. Industry experts and researchers provide an authoritative and concise analysis of the Dimethyl Ether (DME) & R-DME Market, covering key aspects such as growth drivers, challenges, restraints, developments, and opportunities. This report delivers a precise evaluation of shifting market dynamics and emerging trends. Additionally, it offers a…
DME Service Solutions Partners with the AAHomecare
DME Service Solutions, a leader in providing B2B outsourcing solutions specializing in healthcare, is thrilled to announce its partnership with the American Association for Homecare (AAHomecare). This partnership allows DME Service Solutions to engage with a community dedicated to advancing quality care and operational efficiency in the homecare industry.
AAHomecare has served the home medical equipment (HME) industry for nearly four decades, advocating for improved access to quality homecare products…
Global Airport Ground DME Market Analysis (2020-2025)
Global Info Research offers a latest published report on Airport Ground DME Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Airport Ground DME Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure…
Global Durable Medical Equipment (DME) Market Insights, Forecast
Durable Medical Equipment (DME) is a medical equipment that durable, can be used in the home and have at least 3 years of life expectancy. The prevalence of chronic conditions, such as heart disorders, cancer, gynecological disorders, and neurological disorder is on a rise, demand of long term care and hospitalization for treatment of these disorders is anticipated to facilitate the demand for durable medical equipment. The global Durable Medical…
Durable Medical Equipment (DME) Global Market 2019
Press Release – 30 Jan 2019
Research and Development News --
. .
Latest Update "Global Durable Medical Equipment (DME) Market By Type, By Therapeutic and monitoring Devices Type, By End User, By Region, By Country (2018 Edition) - Forecast to 2023-By Type (Personal Mobility devices, Therapeutic and Monitoring Devices, Medical Furniture, Others), By Sub-Type (Oxygen Equipment, Blood Sugar Monitors, Continuous Passive Motions, Nebulizers, Other Devices), By End User (Hospitals and Clinics,…
Dimethyl Ether (DME) Market - Asia Pacific is a major market for DME | Mitsubish …
Majority of the DME manufactured these days is an end-product of two-step process where the first step involves methanol generation with the help of natural gas or coal being used a feedstock. And the second step involves dehydration of methanol for the production of DME. Dimethyl Ether has the potential of replacing diesel in the conventional engines with small modifications that need to be made in the fuel injecting systems.…
